Novo Nordisk A/S
NOVO-B
Clasificación en acciones
#108
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Precio por acción
$39.24
Capitalización bursátil
$173.16B
Cambio (1 día)
-5.26%
Cambio (1 año)
-28.83%
País
DK
Comercio Novo Nordisk A/S (NOVO-B)
Categoría
Healthcare
EPS de Novo Nordisk A/S (NOVO-B)
EPS a fecha de December 2025 TTM: $3.62
Según los últimos informes financieros y el precio de las acciones de Novo Nordisk A/S, el EPS actual de la empresa (TTM) es $3.62. Al final del año 2026, la empresa tenía un EPS de 0 igual a al EPS de 2026, que fue de 0.
Historial de EPS de Novo Nordisk A/S desde 2026 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $29.89 | 725.53% |
US
|
|
| $6.60 | 82.29% |
US
|
|
| $3.55 | -1.95% |
US
|
|
| $1.26 | -65.20% |
US
|
|
| $20.39 | 463.12% |
CH
|
